Komori
Zeria Pharmaceutical (4559) · InitiativeAdvanced

Enabling Diverse Talent to Thrive and Developing Human Resources

First written in FY2023. 3 of 4 entries say "Advanced", first in FY2024. Latest entry: FY2026.

4entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023AdvancedFY2024 – FY20262023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Human Capital Investment, Development and Retention of Diverse TalentA theme 401 companies write about · 3 as a headwind · 411 as a tailwind

The whole theme swung hardest in 2020: 5 of 38 companies on the "Worse" side.

108 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 193 companies compared. The sentences above are computed from all 193.Comparing 200 of the theme's 414 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「a. We are focusing on developing digital talent and promoting the acquisition of certifications such as the IT Passport, with 211 employees having obtained them as of the end of March 2026. b. In fiscal 2025, we conducted information security and IT literacy training and other programs for all employees a total of 5 times」

    The number of employees who had obtained certifications such as the IT Passport increased from 180 in the previous fiscal year to 211, and training for all employees was conducted 5 times in fiscal 2025.
  2. FY2025AdvancedAnnual report

    「a. We are focusing on developing digital talent and promoting the acquisition of certifications such as the IT Passport, with 180 employees having obtained them as of the end of March 2025. b. In fiscal 2024, we conducted information security and IT literacy training and other programs for all employees a total of 5 times, and will continue to do so.」

    The number of digital talent employees who had obtained certifications such as the IT Passport increased from 160 to 180, and information security and IT literacy training for all employees was conducted 5 times in fiscal 2024.
  3. FY2024AdvancedAnnual report

    「a. We promote the acquisition of certifications such as the IT Passport, and 160 employees had obtained them as of the end of March 2024. b. We conduct information security and IT literacy training and other programs for all employees 4 times a year. We aim to continue conducting these programs at least 4 times a year.」

    The company disclosed measurable initiatives for developing digital talent, including 160 employees obtaining certifications such as the IT Passport and conducting training for all employees 4 times a year.
  4. FY2023First statedAnnual report

    「Accordingly, in developing our employees, we embrace the principle that people are our most valuable asset and strive to enhance our education and training systems to develop people capable of meeting society's expectations and earning its trust. As a pharmaceutical manufacturer directly involved with people's lives, we take this responsibility seriously. In addition to ensuring that employees understand specialized business knowledge and codes of conduct, we foster the qualities and character expected of outstanding members of society.」

    Human resources were positioned as important management resources and assets, with education and training, dissemination of specialized knowledge and codes of conduct, and development of personal qualities and character identified as initiatives.
Moved together

"Stable and Consistent Dividends and Strengthening Retained Earnings" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333333★123456
  1. ★This thread
  2. 1Stable and Consistent Dividends and Strengthening Retained Earnings3×
  3. 2Strengthening the Foundation as a Global Company3×
  4. 3Growth of the Prescription Pharmaceutical Business Driven by Asacol, Acofide, and Entocort3×
  5. 4Enhancing the New Drug Pipeline and Consumer Healthcare Products3×
  6. 5Progress in Clinical Trials and Regulatory Filings for Multiple Products3×
  7. 6Expansion of overseas sales3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.